Barnett v. Wyeth

381 F. Supp. 2d 421, 62 Fed. R. Serv. 3d 727, 2005 U.S. Dist. LEXIS 21232
CourtDistrict Court, E.D. Pennsylvania
DecidedMay 25, 2005
DocketNo. 1203; No. CIV.A. 03-20460
StatusPublished
Cited by1 cases

This text of 381 F. Supp. 2d 421 (Barnett v. Wyeth) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Barnett v. Wyeth, 381 F. Supp. 2d 421, 62 Fed. R. Serv. 3d 727, 2005 U.S. Dist. LEXIS 21232 (E.D. Pa. 2005).

Opinion

MEMORANDUM AND PRETRIAL ORDER NO. 5261

BARTLE, District Judge.

Plaintiff, Cheryl Yvonne Barnett, has filed this action against Wyeth for damages arising out of her alleged ingestion of Wyeth’s diet drug, Redux. Before the court is the motion of Wyeth to dismiss with prejudice because of fraud and to impose sanctions on plaintiff. In Pretrial Order (“PTO”) No. 5096, we ordered counsel for plaintiff whose names appear on the complaint1 to appear before the court and show cause why sanctions should not be imposed on them as well as on plaintiff.2 See PTO No. 5096 (E.D.Pa. Apr. 28, 2005). Pursuant to PTO No. 5096, Richard N. Laminack, Esquire, who signed the complaint, appeared before this court on May 17, 2005 and accepted full responsibility for whatever acts or omissions are attributable to counsel.

Plaintiff, a citizen of Texas, filed this suit against Wyeth in the District Court of Bexar County, Texas, on May 27, 2003. The case was later removed to the United States District Court for the Western District of Texas and then transferred to the undersigned as the transferee judge in multi-district litigation (“MDL”) 1203, the mass tort litigation involving Wyeth’s diet drugs Pondimin and Redux. Plaintiffs complaint also named as defendants Wyeth’s related companies, Wyeth Pharmaceuticals, Wyeth-Ayerst Laboratories, and A.H. Robins Company, Inc., as well as two non-diverse corporate employees of Wyeth. On April 18, 2005, we granted [423]*423Wyeth’s unopposed motion to dismiss the corporate employees on the ground that they were fraudulently joined. See PTO No. 5006 (E.D.Pa. Apr. 18, 2005).

In her complaint, prepared and signed by her attorney, plaintiff alleges various state claims arising from her use of Redux. She avers that she “suffers from serious adverse health affects [sic] including heart valve damage” as a result of ingesting Redux “from February, 1989, through June, 1989.” Compl. ¶¶ 3-5. Attached as exhibits to her complaint are copies of prescription records from Super S Pharmacy. The first one, dated February 12, 1989, is for 30 15MG Redux capsules and instructs plaintiff to “Take One Capsule Daily By Mouth For 30 Days.” It also reads “Use Before 3/13/89.” The second one, dated April 2, 1989, is for 60 15MG Redux capsules and advises plaintiff to “Take One Capsules [sic] Twice a Day By Mouth For 60 Days.” It contains a “Use Before” date of 6/3/89. Both labels contain plaintiffs name, the address and phone number for Super S Pharmacy, and the name of the prescribing physician, Dr. Mil-lenizer.

The complaint, it turns out, is false in three material respects. First, it is undisputed that Redux was not available in the United States until June, 1996. See In re Diet Drugs Prods. Liab. Litig., CIV.A. No. 99-20593, PTO No. 1415, 2000 WL 1222042, at *1 (E.D.Pa. Aug. 28, 2000). Accordingly, plaintiff could not have purchased Redux in Texas in 1989 as stated in her complaint. What is especially egregious is that her counsel knew that Redux was not marketed in this country until seven years after the dates that were included in the pleading he signed. Second, there is no Dr. Millenizer practicing medicine in Texas. The use of that name is obviously a fabrication.3 Finally, there is no Super S Pharmacy at 3708 East Commerce Street, San Antonio, Texas. The address is a parking lot for a bar called the TNT Saloon, which is located at 3710 East Commerce Street. Since the 1970’s, 3708 East Commerce Street has been a parking lot and 3710 East Commerce Street has been a bar or night club.4 It goes without saying that plaintiff could not have had her prescriptions for Redux filled at the Super S Pharmacy described.

The fabrications were not limited to the complaint signed by counsel. They were repeated in other documents plaintiffs counsel submitted to Wyeth. As a prerequisite to initiating suit, plaintiff submitted a Blue Form5 declaring her intent to register for benefits under the Nationwide Class Action Settlement Agreement (“Settlement Agreement”) in In re Diet Drugs, Phentermine, Dexfenfluramine, Products Liability Litigation; Brown v. American Home Products Corporation, CIV.A. No. [424]*42499-20593, 2000 WL 1222042 (E.D.Pa. Aug. 28, 2000) (PTO No. 1415) and an Orange Form # 2, declaring her intent to exercise an intermediate opt-out from that settlement. Wyeth’s Mot. to Dismiss, Exs. 8, 9. Both forms state that plaintiff is represented by attorney Richard Laminack. Plaintiff signed both her Blue Form and Orange Form under penalty of perjury attesting that she qualified for the benefits for which she was registering under the terms of the Settlement Agreement. This, of course, was not true. In addition, in or around August, 2004, over a year after the complaint was filed, plaintiffs counsel prepared and served on Wyeth her Fact Sheet, which contained the identity of her medical providers. See PTO Nos. 22, 155 and 2930. Her Fact Sheet falsely repeated that she was prescribed Redux in 1989 by “Dr. Millinizer” or “Dr. Millenizer.”6 See Barnett Fact Sheet at 11, 14; Wyeth’s Mot. to Dismiss, Ex. 4.

Thereafter, in September, 2004, Wyeth noticed plaintiffs deposition twice. The first deposition, which was scheduled for September 2, was canceled at the request of plaintiffs counsel. Wyeth noticed plaintiffs deposition for the second time for September 16, 2004, but plaintiff and her counsel failed to appear. Plaintiffs counsel simply responded to the second notice of deposition by filing a motion to quash in which he stated that “the O’Quinn Firm [Mr. Laminack’s firm] and Ms. Cheryl Barnett have reached an impasse in the prosecution of her case currently pending against Wyeth which will preclude the O’Quinn Firm’s representation of Ms. Barnett in the future.” Pi’s Mot. to Quash at 2 dated Sept. 16, 2004.7 However, plaintiffs counsel never advised Wyeth that the complaint or other documents served on Wyeth contained material fabrications. Nor did he take any steps at that time to withdraw as plaintiffs’ counsel. On October 8, 2004, Wyeth filed a “motion to compel plaintiffs deposition as related to fraudulent claim that she was injured by ingesting Redux in 1989.” Plaintiffs counsel did not respond to the motion.

At the recent hearing before this court, Mr. Laminack represented that late last summer when Wyeth brought the fraudulent claims to his attention, Mr. Laminack told Wyeth not to spend any more money on the case and not to work on the case because he “will make this case go away.” (Tr. 5/17/05 at 65, 67). He also stated that he had told Wyeth that neither he nor plaintiff would appear at the deposition. (Tr. 5/17/05 at 69). Unfortunately, he did not “make this case go away” and thus forced Wyeth to spend more money. He took no action to withdraw as counsel or dismiss the case until May 13, 2005, after Wyeth had moved to dismiss and to obtain sanctions and after this court had entered PTO No. 5096 requiring plaintiffs counsel to appear and show cause why sanctions should not be imposed on them. On that date, plaintiffs counsel finally served on Wyeth a proposed stipulation of dismissal with prejudice. However, it provides that the parties would bear their own costs for the litigation.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
381 F. Supp. 2d 421, 62 Fed. R. Serv. 3d 727, 2005 U.S. Dist. LEXIS 21232, Counsel Stack Legal Research, https://law.counselstack.com/opinion/barnett-v-wyeth-paed-2005.